Categorynews

ReForm Biologics and MilliporeSigma Announce a Licensing Agreement for Excipient Development and Commercialization

February 10, 2020 Off By BusinessWire

WOBURN, Mass.–(BUSINESS WIRE)–ReForm Biologics LLC, a pharmaceutical technology company developing innovative platforms to improve biologic formulations and MilliporeSigma today announced a global license agreement and collaboration to commercialize proprietary ReForm excipients used in biotherapeutic formulations. The Life Science business of Merck KGaA, Darmstadt, Germany operates as MilliporeSigma in the U.S. and Canada.

Under the agreement, MilliporeSigma and ReForm Biologics will conduct research, development and qualification of ReForm Biologics’ excipients for pharmaceutical use. MilliporeSigma will fund the research and development and be responsible for global commercialization, GMP manufacturing, and sale of ReForm Biologics’ excipients to MilliporeSigma’s customers for use in biologic formulations. ReForm Biologics will receive revenues from MilliporeSigma for sublicensing ReForm Biologics’ technology to MilliporeSigma’s customers in biologic formulations.

“MilliporeSigma is a global leader in providing pharmaceutical excipients for biologic formulation. This agreement will make ReForm Biologics’ excipients available through their GMP manufacturing and distribution network, accelerate our research and development activities, and greatly expand our presence in biological drug development,” said John M. Sorvillo Ph.D., Chief Executive Officer at ReForm Biologics. “As more biologics are being developed to treat a broad range of diseases ranging from cancer to orphan indications, we believe there will be a growing demand for new excipients that can enhance the patient experience, improve patient outcomes, and potentially extend the patent life of a therapeutic.“

About ReForm Biologics

ReForm Biologics has developed a technology platform that transforms the formulation of biotherapeutics for the ultimate benefit of patients. ReForm’s patented technology can extend product life-cycles, enable alternative dosing, and improve manufacturing efficiency for our biopharmaceutical partners. With multiple industry alliances to date, ReForm offers formulation development collaborations and product-specific licenses for a broad spectrum of protein-based therapeutics.

We don’t make biologics — we make biologics better.

www.reformbiologics.com